CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma

American Journal of Clinical Pathology

Volumn 141, Issue 4, 2014, Pages 573-583

  Koh, Young Wha ^a   Park, Chansik ^b   Yoon, Dok Hyun ^b   Suh, Cheolwon ^b   Huh, Jooryung ^b  

^a Ajou University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

CD163; CD68; Colony stimulating factor 1 receptor; Hodgkin lymphoma; Prognosis

Indexed keywords

BLEOMYCIN; CD163 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING 1 RECEPTOR; COLONY STIMULATING FACTOR 1; DACARBAZINE; DOXORUBICIN; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG; VINBLASTINE; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; CHLORDANE; COLONY STIMULATING FACTOR RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLASSICAL HODGKIN LYMPHOMA; DISEASE ASSOCIATION; DISEASE COURSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; CD163; COLONY-STIMULATING FACTOR 1 RECEPTOR; GENETICS; HODGKIN DISEASE; MACROPHAGE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

CD163; CD68; COLONY-STIMULATING FACTOR 1 RECEPTOR; HODGKIN LYMPHOMA; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; FEMALE; HODGKIN DISEASE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84899491428     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPR92TDDFARISU     Document Type: Article

References (33)

1. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J. 2009;15:161-163.
2. Hasenclever D, Diehl V, Armitage JO, et al, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339:1506-1514. (Pubitemid 28543499)
3. Salloum E, Doria R, Schubert W, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 1996;14:2435-2443. (Pubitemid 26300109)
4. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875-885.
5. Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol. 2012;88:292-305.
6. Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica. 2011;96:269-276.
7. Porrata LF, Ristow K, Colgan J, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin lymphoma. Haematologica. 2012;97:262-269.
8. Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17:871-880.
9. Koh YW, Kang HJ, Park C, et al. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol. 2012;138:846-854.
10. Sherr CJ, Rettenmier CW, Sacca R, et al. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell. 1985;41:665-676. (Pubitemid 15243374)
11. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004;14:628-638. (Pubitemid 39440612)
12. Zins K, Abraham D, Sioud M, et al. Colon cancer cell-derived tumor necrosis factor-α mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res. 2007;67:1038-1045.
13. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78. (Pubitemid 38082155)
14. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266. (Pubitemid 43121975)
15. Bartelmez SH, Stanley ER. Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineage specific HGF: assay of hemopoietin-1. J Cell Physiol. 1985;122:370-378. (Pubitemid 15127508)
16. Byrne PV, Guilbert LJ, Stanley ER. Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues. J Cell Biol. 1981;91:848-853. (Pubitemid 12211174)
17. Paietta E, Racevskis J, Stanley ER, et al. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res. 1990;50:2049-2055. (Pubitemid 20115074)
18. Espinosa I, Beck AH, Lee CH, et al. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol. 2009;174:2347-2356.
19. Jia JB, Wang WQ, Sun HC, et al. High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist. 2010;15:732-743.
20. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67:5064-5066. (Pubitemid 46997238)
21. Richardsen E, Uglehus RD, Due J, et al. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology. 2008;53:30-38. (Pubitemid 351861980)
22. Steidl C, Diepstra A, Lee T, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012;120:3530-3540.
23. Ullrich K, Wurster KD, Lamprecht B, et al. BAY 43-9006/ Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br J Haematol. 2011;155:398-402.
24. Moskowitz CH, Younes A, de Vos S, et al. CSF1R inhibition by PLX3397 in patients with relapsed or refractory Hodgkin lymphoma: results from a phase 2 single agent clinical trial. In: Proceedings of the 54th ASH Annual Meeting and Exposition. Washington, DC: ASH; 2012. Abstract 1638.
25. Huh J, Cho K, Heo DS, et al. Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. Am J Hematol. 1999;60:205-214. (Pubitemid 29108771)
26. Yeung YG, Stanley ER. Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction. Mol Cell Proteomics. 2003;2:1143-1155.
27. Scholl SM, Pallud C, Beuvon F, et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst. 1994;86:120-126. (Pubitemid 24040150)
28. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004:64:7022-7029. (Pubitemid 39331012)
29. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727-740.
30. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122:794-801. (Pubitemid 39434761)
31. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555. (Pubitemid 35223554)
32. Ohri CM, Shikotra A, Green RH, et al. The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS One. 2011;6:e21874.
33. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686. (Pubitemid 39457982)